Orion Portfolio Solutions LLC Cuts Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

Orion Portfolio Solutions LLC decreased its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 4.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 96,548 shares of the company’s stock after selling 4,102 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Stevanato Group were worth $2,104,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in STVN. Blair William & Co. IL purchased a new position in Stevanato Group in the 4th quarter valued at approximately $466,000. Artisan Partners Limited Partnership boosted its holdings in Stevanato Group by 28.7% in the fourth quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company’s stock valued at $51,333,000 after purchasing an additional 524,989 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Stevanato Group by 34.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 19,358 shares of the company’s stock worth $458,000 after purchasing an additional 4,976 shares during the period. Pier Capital LLC raised its position in Stevanato Group by 2.9% in the 4th quarter. Pier Capital LLC now owns 381,624 shares of the company’s stock valued at $8,316,000 after purchasing an additional 10,627 shares in the last quarter. Finally, Zions Bancorporation N.A. boosted its stake in shares of Stevanato Group by 29.7% in the 4th quarter. Zions Bancorporation N.A. now owns 68,017 shares of the company’s stock valued at $1,482,000 after buying an additional 15,555 shares during the period.

Stevanato Group Stock Performance

Shares of STVN stock opened at €20.98 ($22.80) on Thursday. The stock’s 50-day moving average is €20.81 and its two-hundred day moving average is €20.62. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.00) and a 1 year high of €31.61 ($34.36). The firm has a market cap of $6.35 billion, a price-to-earnings ratio of 44.64, a PEG ratio of 7.18 and a beta of 0.60.

Stevanato Group (NYSE:STVN) last released its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, hitting the consensus estimate of €0.20 ($0.22). The company had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Bank of America raised their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a report on Friday, December 13th. William Blair reaffirmed an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. UBS Group dropped their target price on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a report on Friday, March 7th. Finally, Wolfe Research started coverage on Stevanato Group in a research report on Friday, December 13th. They set an “outperform” rating and a $28.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of €25.70 ($27.93).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.